{SÉLECTION} #16 - Marc de Garidel, CEO Abivax, Take risks to build something meaningful
Épisode de Pharma Minds par Nathalie Lahitte · 4 août 2025 · 1 h 10 min
In the fascinating world of Pharma, a visionary and pragmatic man, @Marc de Garidel, stands out. His journey began in a down-to-earth family, setting the stage for an extraordinary adventure.
Careers are rarely planned, but his appetite for adventure emerged early:
He launched Amgen in Europe.
He developed Ipsen in the United States.
These initial steps marked the commencement of an incredible journey in the pharmaceutical world, teaching him how Pharma truly operates, especially regarding access today.
Then, he embarked on a more entrepreneurial path as the CEO of biotechs:
Corvidia Therapeutics, sold to Novo Nordisk in August 2020.
CinCor Pharma, sold to AstraZeneca in February 2023.
Currently, he is the CEO of Abivax.
This experience taught him that taking risks fuels innovation, and every failure is a step towards success.
Today, as the CEO of Abivax, Marc shares his wealth of experience with the Pharma community. His story is an invitation to embrace the unknown, confront challenges with courage, and see every opportunity as a new adventure.
Marc encourages bold minds to pursue their passions, dare to take risks, and view every obstacle as a step towards success.
Marc is a passionate individual, a grounded soul unafraid to dream big for patients.
His legacy serves as a timeless reminder that adventure, wisdom, and courage constitute a potent trio for those aspiring to push the boundaries of medical innovation.
-
Update since the recording of the episode:
This interview took place in August 2023. In October, Abivax entered the Nasdaq. Despite a challenging stock market context, this is the largest IPO in the history of a French biotech. 🚀
-
Notes and episode references
Links :
Abivax : https://www.abivax.com/
The LinkedIn post if you want to share your feedback or ask questions:
https://www.linkedin.com/posts/nathalielahitte_in-the-fascinating-world-of-pharma-marc-activity-7132294793195352064-HKrE?utm_source=share&utm_medium=member_desktop
-
1. Working together!
THE FARM & CO develops your visibility in Pharma using the strength of your therapeutic commitment, the uniqueness of your personality and the power of social networks. Build a presence aligned with your values. Ghostwriting, content creation & conversational tools.
2. My newsletter
In my newsletter Pharma futurista, 2x/month, I jump into our society's evolutions and apply them to the future of Pharma. It's a short, 3-minute read on a subject that appeals to me. To receive it, you can subscribe here: https://nathalielahitte.substack.com/ or directly on my LinkedIn profile.
3. Get in touch with me!
If you like the podcast, the best way to tell me or share your thoughts is on the Apple podcast app. It really helps me out, so don't hesitate to share!
If you'd like to ask me questions or follow my progress, you can do so on LinkedIn @nathalie lahitte .
Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.
Autres épisodes de « Pharma Minds »
- #53 - Libérer du temps soignant : le pari d'un ingénieur à la Clinique Pasteur 19 octobre 2026
- [EXTRAIT] « On a toujours fait comme ça » : comment faire accepter le changement ? avec Loïc Lagarde 18 octobre 2026
- "Europe's Access Dilemma" (BONUS) - The Innovation Wave? Europe’s Payers Aren’t Convinced 12 octobre 2026
- "Europe's Access Dilemma" (5/5) - "Germany has a target on its back" What will Europe give up? 5 octobre 2026
- "Europe's Access Dilemma" (4/5) - Pharma Innovation: Your 8-Year Competitive Window Is Now Just 3 28 septembre 2026
- "Europe's Access Dilemma" (3/5) - MFN Is Already Changing Pharma Launch Strategy. Here’s How to Prepare. 21 septembre 2026
- "Europe's Access Dilemma" (2/5) - Europe Can't Pay More For Innovation: The Case For Co-developing With Asia 14 septembre 2026
- "Europe's Access Dilemma" (1/5) - Europe Is Losing Access to New Medicines. Here’s Why. 7 septembre 2026
- [Insights] Produits frontières : transformer la réglementation en avantage stratégique 2 septembre 2026
- "Executing differently takes courage" (5/5) - From managing global subsidiaries to walking the talk : when execution becomes personal 17 août 2026
- "Executing differently takes courage" (4/5) - Biotech survival and resource allocation : why execution is about choosing what not to do 10 août 2026
- "Executing differently takes courage" (3/5) - Trusting the ground : navigating volatility, growth and partnerships across the EEMEA zone 3 août 2026
- "Executing differently takes courage" (2/5) - The Chinese pharma ecosystem : balancing systemic scale and constant reinvention 27 juillet 2026
- "Executing differently takes courage" (1/5) Transforming Vidal : how a 20-year vision turned a paper book into digital infrastructure 20 juillet 2026
- [Insights] Groupements de pharmacies : ce qu’il faut retenir du rapport IGF-IGAS, avec Hugues Villey Desmeserets 8 juillet 2026
À propos du podcast
Bienvenue dans Pharma minds, le podcast qui vous emmène dans une aventure captivante à travers la Pharma et la Santé d'aujourd'hui ! Je suis votre hôte, Nathalie Lahitte. Mon objectif ? Découvrir comment des personnalités influentes ont contribué à façonner ce secteur. À chaque épisode, nous…
Épisodes similaires
- Radio et DAB+ : y aura-t-il un jour de la vidéo FM ? – Ça marque ! Le podcast qui décrypte les stratégies de communication digitale et les innovations du marketing éditorial
- Webinaire / découvrir les ETF avec Amundi : comprendre, choisir et investir – Webinaire
- Arrêt maladie, Indemnités limitées à un an : ces enjeux RH que les DRH doivent poser sur la table du CoDir dès maintenant – Capital Humain – Travail, ressources humaines et santé mentale
- [AZIMUT ENTREPRENDRE | 1/3] - 15 000 abonnés sans montrer son visage - Safia Hadidi – Donne le Rythme
- 1000 ads en une semaine : comment Flytex scale ses ads Meta avec l'IA – Le Rendez-vous E-commerce
- La France peut-elle encore éviter une crise financière ? – Ecorama
Tous les épisodes de Pharma Minds · Plus de podcasts Business